Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China

Tuesday, October 16, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

SUZHOU, China, Oct. 16, 2018 /PRNewswire/ -- Alphamab Oncology announced that it has received US FDA's IND approval for its

proprietary HER2 bispecific antibody (product code: KN026), and KN026 is anticipated to enter clinical development later in the US. With the earlier IND approval for KN026 in China, Alphamab
Oncology has recently initiated the phase I clinical trial there, and the trial is going well as expected.

Based on the company's proprietary Fc-based bispecific platform (CRIB), Alphamab Oncology developed anti-HER2 heterodimeric antibody KN026, which has the same format of natural IgG antibody. KN026 binds to two separate epitopes on HER2. KN026 is manufactured through a robust conventional antibody production process. The process has been validated by multiple large-scale (up to 1,000 liters) batches.

KN026 has demonstrated an excellent pre-clinical profile in binding affinity, efficacy, safety, and pharmacokinetics. It showed better efficacy activity in about 40% of HER2+ tumor cell lines and multiple in vivo tumor models, as compared to the combo of Trastuzumab and Pertuzumab. KN026 is expected to offer cancer patients a new and potentially improved therapeutic option. Currently the global annual sales of Trastuzumab and Pertuzumab is about $10 billion.

"We are very pleased with the FDA's IND approval for KN026, and it shows the agency's initial recognition for the quality of this innovative bispecific biologics. It also represents the very first US IND approval for a bispecific antibody discovered and developed by China-based biotech or pharmaceutical companies," said Dr. Ting Xu, Chairman of the Board and CEO of Alphamab Oncology. "With this world-class bispecific platform, we also look forward to partnering with pharma/biotech companies worldwide to develop more bispecific therapeutics."

Alphamab Oncology has been collaborating with leading oncologists and will study KN026 in multiple clinical trials for patients of breast cancer, gastric cancer, and lung cancer with HER2 overexpression.

About Alphamab Oncology:

Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms, including bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/immunology. We strive to develop next-generation or best in class medicines to address global unmet medical needs. Visit http://www.alphamabonc.com for more information.

For media enquiries:

Ms. Tingting ZhangAlphamab Oncology+86-512-6285-0800 x8807tingtingzhang@alphamabonc.com

Cision View original content:http://www.prnewswire.com/news-releases/alphamab-oncologys-her2-bispecific-antibody-kn026-gained-us-ind-approval-phase-i-clinical-trial-started-in-china-300731656.html

SOURCE Jiangsu Alphamab Biopharmaceuticals Co., Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store